Epstein-Barr virus infection and associated products (LMP, EBNA2, vIL-10) in nodal non-Hodgkin's lymphoma of human immunodeficiency virus-negative Japanese.
Sixty cases of B-cell nodal non-Hodgkin's malignant lymphoma (B-ML), and 46 cases of T-cell nodal lymphoma (T-ML) were surveyed for Epstein-Barr virus (EBV) genomes, RNA, and associated proteins. We used a Southern blot analysis, polymerase chain reaction (PCR), and EBV-encoded small RNA-1 (EBER-1) in situ hybridization to investigate the presence of EBV. We performed an immunohistochemical study on EBV-related oncoproteins, such as EBV-determined nuclear antigen-2 (EBNA-2), latent membrane protein (LMP), and viral interleukin-10 (vIL-10). In addition, we also analyzed the terminal repetitive sequence of EBV (EBV-TR) to investigate the EBV-infected cell clonality. Non-Hodgkin's lymphomas were grouped into three types by number of EBV-infected cells: I) almost all lymphoma cells showed an EBV presence; II) some scattered lymphoma cells showed an EBV presence; and III) only a few cells showed such a presence, which was probably due to a latent EBV infection. In 25 of 60 B-MLs, EBV-infected cells were found; 7 were type I, 1 was type II, and 17 were type III. In 27 of 46 T-MLs, EBV-infected cells were found; no cases were type I, 5 cases were type II, and 22 cases were type III. Seven B-MLs and 3 T cell lymphomas showed clonal TR bands. Expression of EBNA-2 was found in only three B-MLs, whereas LMP was seen in four B-MLs and six T-MLs. All EBNA-2/LMP-positive cases showed an EBV presence. In B-MLs, expression of EBNA-2 and LMP was detected in almost all lymphoma cells; in T-MLs, however, LMP was found in only a small portion of the lymphoma cells. Expression of IL-10 was closely associated with LMP. In summary, it was thus speculated that EBV infection was associated with the various states of lymphomagenesis.
Ohshima
K
K
Department of Pathology, School of Medicine, Fukuoka University, Japan.
Suzumiya
J
J
Tasiro
K
K
Mukai
Y
Y
Tanaka
T
T
Kato
A
A
Kikuchi
M
M
D000956:Antigens, Viral / Q000032:analysis*; D002471:Cell Transformation, Neoplastic; D002999:Clone Cells / Q000821:virology; D003043:Cocarcinogenesis; D015897:Comorbidity; D004268:DNA-Binding Proteins / Q000032:analysis*; D019309:Epstein-Barr Virus Nuclear Antigens; D018023:HIV Seronegativity; D006566:Herpesviridae Infections / Q000453:epidemiology*; D004854:Herpesvirus 4, Human / Q000302:isolation & purification* / Q000472:pathogenicity; D006801:Humans; D015994:Incidence; D016753:Interleukin-10; D007564:Japan / Q000453:epidemiology; D008199:Lymphadenitis / Q000453:epidemiology / Q000821:virology; D016393:Lymphoma, B-Cell / Q000737:chemistry / Q000453:epidemiology / Q000821:virology; D008228:Lymphoma, Non-Hodgkin / Q000737:chemistry / Q000453:epidemiology / Q000821:virology*; D016399:Lymphoma, T-Cell / Q000737:chemistry / Q000453:epidemiology / Q000821:virology; D014411:Neoplastic Stem Cells / Q000821:virology; D014412:Tumor Virus Infections / Q000453:epidemiology*; D014763:Viral Matrix Proteins / Q000032:analysis*; D014764:Viral Proteins / Q000032:analysis*
D000956:Antigens, Viral; C066460:BCRF1 protein, Human herpesvirus 4; D004268:DNA-Binding Proteins; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D019309:Epstein-Barr Virus Nuclear Antigens; D014763:Viral Matrix Proteins; D014764:Viral Proteins; D016753:Interleukin-10